北京市君泽君律师事务所 关于美年大健康产业控股股份有限公司 发行股份购买资产暨关联交易 相关主体买卖股票情况自查报告的 专项核查意见 中国北京东城区金宝街 89 号金宝大厦 11 层 邮政编码:100005 11F, Jinbao Tower, 89 Jinbao Street, Dongcheng District, Beijing 10005, P.R.C. Tel: 861066523388 Fax: 861066523399 Http://www.junzejun.com 北京市君泽君律师事务所 关于美年大健康产业控股股份有限公司 发行股份购买资产暨关联交易 相关主体买卖股票情况自查报告的 专项核查意见 君泽君[2025]证券字 2025-019-3-1 致：美年大健康产业控股股份有限公司 北京市君泽君律师事务所接受美年大健康产业控股股份有限公司（以下简称 "美年健康"或"上市公司"）的委托，担任其发行股份购买资产暨关联交易事 项（以下简称"本次交易"或"本次重组"）的中国法律顾问并出具法律意见书。 根据《上市公司重大资产重组管理办法》《上市公司信息披露管理办法》《公 开发行证券的公司信息披露内容与格 ...

粤开证券股份有限公司关于美年大健康产业控股股份有限公司 发行股份购买资产暨关联交易相关主体买卖股票情况的自查报 一、本次交易的内幕信息知情人自查期间 本次交易的内幕信息知情人买卖股票情况的自查期间为公司首次披露《美年 大健康产业控股股份有限公司发行股份购买资产暨关联交易预案》前 6 个月至 《美年大健康产业控股股份有限公司发行股份购买资产暨关联交易报告书（草 案）》披露前一日止，即 2024 年 10 月 14 日至 2025 年 7 月 11 日（以下简称"自 查期间"）。 二、本次交易的内幕信息知情人核查范围 本次交易的内幕信息知情人核查范围包括：上市公司及其董事、监事、高级 管理人员或主要负责人，上市公司的实际控制人及其相关知情人员，交易对方及 其董事、监事、高级管理人员、主要管理人员或主要负责人，标的资产及其董事、 监事、高级管理人员或主要负责人，本次交易相关中介机构及其具体业务经办人 员，其他知悉本次交易内幕信息的法人和自然人，以及上述人员的直系亲属（配 偶、父母、年满18周岁的子女）。 三、本次交易的内幕信息知情人及其直系亲属买卖上市公司股票的情况 根据中国证券登记结算有限责任公司深圳分公司出具的 ...

证券时报·数据宝统计显示，美年健康今日收盘价为5.14元，下跌0.19%，日换手率为1.64%，成交额为 3.26亿元，全天主力资金净流入1486.36万元，近5日该股累计上涨0.98%，近5日资金合计净流入262.70 万元。 两融数据显示，该股最新融资余额为6.78亿元，近5日减少4626.18万元，降幅为6.39%。（数据宝） 7月25日美年健康大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折溢 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 价（%） | 业部 | | | 550.00 | 2585.00 | 4.70 | -8.56 | 机构专 | 海通证券股份有限公司杭州环城 | | | | | | 用 | 西路证券营业部 | | 400.00 | 1880.00 | 4.70 | -8.56 | 机构专 | 海通证券股份有限公司杭州环城 | | | | | | 用 | 西路证券营业部 | | 300.00 | 1410.00 | 4.70 | -8.56 | 机构专 | ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002044 证券简称：美年健康 公告编号：2025-050 美年大健康产业控股股份有限公司 关于召开2025年第一次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 美年大健康产业控股股份有限公司（以下简称"公司"）2025年第一次临时股东大会现场会议的召开地点 为上海市静安区灵石路697号健康智谷9号楼三楼公司会议室，敬请投资者特别留意。 根据公司于2025年7月11日召开的第九届董事会第十次（临时）会议，定于2025年7月28日召开公司2025 年第一次临时股东大会，本次股东大会将采用股东现场记名投票与网络投票表决相结合的方式召开， 《关于召开2025年第一次临时股东大会的通知》（公告编号：2025-047）已于2025年7月12日披露在 《中国证券报》、《上海证券报》、《证券时报》、《证券日报》和巨潮资讯网 （www.cninfo.com.cn）。现就本次股东大会的有关事宜发布提示性公告如下： 一、本次会议召开基本情况 1、股东大会届次：公司2025年第一次 ...

证券代码：002044 证券简称：美年健康 公告编号：2025-050 美年大健康产业控股股份有限公司 关于召开 2025 年第一次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 美年大健康产业控股股份有限公司（以下简称"公司"）2025 年第一次临时股 东大会现场会议的召开地点为上海市静安区灵石路 697 号健康智谷 9 号楼三楼 公司会议室，敬请投资者特别留意。 根据公司于 2025 年 7 月 11 日召开的第九届董事会第十次（临时）会议，定 于 2025 年 7 月 28 日召开公司 2025 年第一次临时股东大会，本次股东大会将采 用股东现场记名投票与网络投票表决相结合的方式召开，《关于召开 2025 年第 一次临时股东大会的通知》（公告编号：2025-047）已于 2025 年 7 月 12 日披露 在《中国证券报》、《上海证券报》、《证券时报》、《证券日报》和巨潮资讯 网（www.cninfo.com.cn）。现就本次股东大会的有关事宜发布提示性公告如下： 一、本次会议召开基本情况 2）通过互联网投票系统进行 ...

Core Viewpoint - The article highlights a charitable health screening event organized by Ciming Health Checkup Group for retired soldiers, emphasizing the importance of honoring and caring for veterans as a social responsibility and a way to express gratitude for their service [1][4][9]. Group 1: Event Overview - The "Welcoming August 1st, Warming Veterans" charity event took place on July 22, where 29 retired soldiers received health checkups, aiming to enhance their sense of honor, belonging, and happiness [1][4]. - Ciming Health Checkup Group, in collaboration with the Dahongmen Street Office, meticulously planned the event to ensure a memorable experience for the veterans [4][6]. Group 2: Health Services Provided - The health checkup included a comprehensive range of services tailored to the veterans' age and health needs, covering various medical specialties and tests such as internal medicine, external medicine, and cancer screenings [4][12]. - Medical staff provided personalized health guidance based on each veteran's health status, lifestyle, and medical history, ensuring a thorough and caring approach [4][12]. Group 3: Community and Corporate Responsibility - The event was praised by local officials, highlighting the importance of community support for veterans and the ongoing efforts to improve the service and support system for retired military personnel [6][8]. - Ciming Health Checkup Group has previously donated 1.68 million yuan for health checkups for low-income veterans, demonstrating a commitment to social responsibility and the well-being of retired soldiers [8][9]. Group 4: Future Initiatives - Ciming Health Checkup Group plans to continue expanding its charitable services, aiming to provide high-quality health services to a broader audience while fostering a culture of respect and care for veterans [12].

Core Viewpoints - The pharmaceutical and biotechnology sector is experiencing a turning point and structural market trends in the first half of 2025, with a focus on innovative drugs and their supply chain, AI healthcare, and brain-computer interfaces as structural opportunities [3][5] - The A-share pharmaceutical and biotechnology index has increased by 10.10% since the beginning of 2025, outperforming the CSI 300 index by 8.90 percentage points, ranking 4th in industry performance [3][22] - Among 480 listed pharmaceutical and biotechnology companies, 348 have seen their stock prices rise, accounting for 72.5%, with 17 stocks doubling in value [3][40] Investment Logic - The innovative drug sector is accelerating its value reconstruction through business development (BD) overseas, research and commercialization progress, and policy support. In the first half of 2025, over 50 BD transactions for innovative drugs occurred, totaling over $48 billion [5] - Significant clinical data releases and commercialization progress for major drug candidates are expected to drive stock price increases [5] - Policy initiatives, such as the March 2025 government work report emphasizing the support for innovative drugs and medical devices, are providing strong backing for the industry's long-term development [5] Market Performance - The pharmaceutical sector's valuation has seen a short-term recovery but remains at a long-term low, with a PE ratio of 29 times as of mid-2025, slightly above the 50th percentile of the past four years [3][43] - Public fund holdings in the pharmaceutical sector have increased, with the proportion of public funds in A+H shares rising to 9.05% in Q1 2025, a 0.37 percentage point increase [3][58] Sub-industry Performance - The best-performing sub-industries in the pharmaceutical sector include chemical preparations and other biological products, with increases of 25.8% and 24.0%, respectively [3][22] - The pharmaceutical industry is witnessing a structural market trend, with innovative drugs leading the charge, while traditional sectors like vaccines and traditional Chinese medicine have seen slight declines [3][29] Recommended Stocks - A robust portfolio is suggested, including companies such as Heng Rui Medicine, BeiGene, and United Imaging Healthcare, among others [10]

证券代码：002044 证券简称：美年健康 公告编号：2025-049 美年大健康产业控股股份有限公司 关于 5%以上股东权益变动触及 1%刻度的公告 公司股东杭州信投信息技术有限公司保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 | 变动方向 上升□ 下降√ | | 一致行动人 | | | 有√ 无□ | | | --- | --- | --- | --- | --- | --- | --- | | 是否为第一大股东或实际控制人 | | | | 是□ 否√ | | | | 2、本次权益变动情况 | | | | | | | | 股份种类（A 股、B 股等） | | 减持股数（万股） | | | 减持比例（%） | | | A 股 | | 3,921 | | | 1.01 | | | 合 计 | | 3,921 | | | 1.01 | | | 本次权益变动方式（可多选） | | 通过证券交易所的集中交易 | | □ | | | | | | 通过证券交易所的大宗交易 | | √ | | | | 其他 | | | | | □（请注明） | | | 3、本次变动前后，投资者及其一 ...

Core Viewpoint - The article discusses the performance and management of the Rongtong Health Industry Flexible Allocation Mixed Fund A/B, highlighting its net asset growth and the background of its fund manager, Wan Minyuan [1][2]. Fund Performance - As of June 30, 2025, the net assets of the Rongtong Health Industry Flexible Allocation Mixed Fund A/B reached 2.074 billion yuan, reflecting a 1.92% increase from the previous period [1]. - The fund's recent performance includes a 15.0% return over the last three months and a 19.86% return over the past year, with a cumulative return of 166.1% since inception [2]. Fund Manager Background - Wan Minyuan, the fund manager, holds a PhD in Biomedical Science from Sichuan University and has extensive experience in the investment sector, having worked at various securities firms and investment management companies since 2011 [1]. Fund Holdings - The top ten stock holdings of the fund include Yixin Tang, Aibo Medical, Sanyou Medical, Jianzhijia, Kaili Medical, Yangguang Nuohuo, Dongfang Biological, Puri Eye Care, Meihua Medical, and Meinian Health, with a combined holding percentage of 57.00% [2]. Company Overview - Rongtong Fund Management Co., Ltd. was established in May 2001 and is based in Shenzhen, focusing on capital market services, with a registered capital of 125 million yuan [2].

Group 1 - The core viewpoint of the articles highlights that Meinian Health (002044.SZ) is leveraging AI technology to enhance its revenue streams, with projected revenue for the first half of 2025 estimated between 3.96 billion to 4.2 billion yuan, and AI-related revenue exceeding 140 million yuan, reflecting a year-on-year growth of 62.36% [1][2] - The company is actively promoting the conversion from group health checks to individual health checks, aiming to enhance customer retention and increase repurchase rates through strategies like "full journey customer operation" and "private domain transformation" [2] - Meinian Health has entered a strategic partnership with Alibaba's Damo Academy to implement AI technology for multi-cancer screening, which is expected to improve screening efficiency and expand early detection capabilities for asymptomatic populations [2][3] Group 2 - The company is transitioning from a traditional health check service provider to an AI-driven health management solution platform, with significant potential for future platform value as health data becomes increasingly valuable [3] - Efforts to optimize client acquisition strategies and enhance service quality are ongoing, with a focus on maximizing operational efficiency and innovation in revenue generation [1][2]